Next-Generation Sequencing (NGS) for Biologics Safety and Quality Control

Biological products—including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapy (CGT) products—are manufactured using living cells and complex biological processes. As a result, ensuring product safety, purity, and batch-to-batch consistency remains a central challenge in biologics manufacturing.

Tablle 1. Core Quality Risks in Biologics Manufacturing

Quality Risk Category	Typical Sources	Potential Impact
Adventitious agents	Raw materials, cell substrates, environment	Product recalls, patient safety risk
Host cell DNA (HCD) residues	Incomplete purification	Regulatory non-compliance, oncogenic risk
Process variability	Culture conditions, feed strategy	Batch inconsistency, CQAs drift

 Conventional QC assays such as PCR, qPCR, and ELISA are GMP-proven and reliable—but inherently target-limited and hypothesis-driven, leaving blind spots for unknown or emerging risks.

Next-generation sequencing (NGS)—including metagenomic NGS (mNGS), targeted host cell DNA (HCD) sequencing, and transcriptome profiling—enables unbiased, high-resolution, system-level surveillance, redefining biologics quality control. Notably, ICH Q5A, the international guideline for viral safety evaluation of biopharmaceuticals, acknowledges that NGS can, under appropriate circumstances, serve as a substitute for traditional in vivo and in vitro virus testing of cell banks.

 With pharmacopeias such as USP and EP actively advancing NGS standardization, sequencing technologies are rapidly transitioning from R&D tools to GMP-compatible QC platforms.

 1. Adventitious Agent Detection: mNGS Enables Unbiased Pathogen Surveillance

Table 2. Limitations of Traditional Methods

Method	Key Limitations
PCR / RT-PCR	Requires predefined targets; cannot detect novel or mutated agents
ELISA	Antibody-dependent; limited sensitivity for non-enveloped viruses or mycoplasma
In vitro / in vivo assays	Time-consuming (weeks), low sensitivity, incomplete virus coverage

These methods are effective only for known risks, leaving manufacturers vulnerable to unexpected contaminants.

Metagenomic NGS (mNGS): Panoramic Pathogen Surveillance

Metagenomic NGS (mNGS) sequences all nucleic acids (DNA and RNA) present in a sample without prior assumptions and provides a comprehensive safety net throughout cell line development, process validation, and routine QC testing.

A well-known example is the 2010 rotavirus vaccine recall caused by porcine circovirus type 1 (PCV1). PCV1 was not targeted by routine assays, yet retrospective analysis showed that mNGS could have detected the contamination during early process development.

Table 3. Regulatory Momentum for mNGS

Authority	Position on NGS
FDA	Encourages NGS for cell line characterization
EMA	Accepts mNGS as supportive viral safety data
Chinese Pharmacopoeia (2025 draft)	Proposes high-throughput sequencing for adventitious virus testing

 2. Host Cell DNA Residual Quantification: From Single-Target qPCR to Multi-Locus NGS

Regulatory authorities worldwide mandate strict control of residual host cell DNA in biologics. Specifically, residual DNA must not exceed 10 ng per dose, and fragment sizes should remain below 200 bp to minimize the risk of genomic integration. Common production cell lines include CHO, HEK293, NS0, and SP2/0.

While qPCR remains the industry standard, it presents inherent limitations. NGS offers multi-locus quantification, high sensitivity, broad dynamic range, fragment size assessment, and precise source verification, overcoming the inherent limitations of qPCR.

Table 4. Comparison of qPCR and NGS Approaches for Host Cell DNA (HCD) Quantification

Aspect / Feature	qPCR-Based HCD Detection	NGS-Based HCD Quantification
Quantification strategy	Single-locus detection	Multi-locus detection (10–50 conserved genomic regions)
Sensitivity	Limited, affected by inhibitors	Down to ~1 copy/µL
Dynamic range	Narrow	Linear across ≥5 orders of magnitude
Fragment size information	Not available	Direct profiling of DNA fragment sizes
Source verification	Cannot confirm DNA origin	Genome-level alignment ensures host cell specificity

 3. Monitoring Batch Consistency and Process Stability with NGS

Under the Quality by Design (QbD) paradigm, manufacturers are expected to monitor and control process variability continuously. NGS enables molecular-level “process fingerprints” that reveal subtle but meaningful deviations. 

Transcriptome Profiling (RNA-seq)

RNA-seq provides a global view of host cell behavior across batches:

• Confirms consistency of gene expression profiles
• Detects stress responses linked to pH, dissolved oxygen, or feed strategy changes
• Predicts downstream quality risks such as aggregation or glycosylation drift

Industry example: A monoclonal antibody manufacturer identified significant upregulation of ER stress markers (BiP, CHOP) in one batch via RNA-seq. Early intervention prevented increased aggregation in the final product.

Epigenomic Stability (Advanced Applications)

For viral vectors and CGT products:

• ATAC-seq / ChIP-seq assess chromatin accessibility and epigenetic regulation
• Ensure promoter activity and transgene expression stability
• Detect epigenetic silencing risks during long-term production

Regulatory Acceptance and GMP Readiness

NGS implementation in GMP environments requires rigorous validation and control. Regulatory frameworks are rapidly evolving.

Guideline	Key Focus
USP <1033>	Validation of NGS-based biological assays
EP 2.6.33	Standardized NGS workflows for contaminant detection
ICH Q5A(R2)	Recognition of NGS for adventitious virus testing

 NGS -A Future-Ready Biologics QC Strategy

NGS enhances—not replaces—established QC assays. By adding depth, breadth, and molecular-level understanding, NGS enables biologics manufacturers to shift from reactive compliance to proactive quality control.

As regulatory frameworks mature and sequencing technologies become more accessible, NGS is positioned to become a standard, expected element of biologics quality systems.

Adventitious agents	mNGS
Residual host cell DNA	Targeted multi-locus NGS
Batch consistency	RNA-seq–based molecular profiling

 Yeasen NGS Solutions for Biologics Safety & Quality Control

Yeasen provides end-to-end NGS solutions designed specifically for regulated biologics QC environments.

Application	Yeasen Solution Highlights	Product Information
mNGS pathogen detection	Optimized nucleic acid extraction for low biomass samples	Hieff NGS™ OnePot Flash DNA Library Prep Kit (Enzymatic) _ 12316ES
DNA/RNA co-detection	Library prep kits compatible with mixed inputs	Hieff NGSTM DNA&RNA Library Co-Prep Kit_ 13597ES
Host cell DNA quantification	Enzymatic fragmentation & ultra-low DNA recovery	Hieff NGS™ OnePot Pro DNA Library Prep Kit V4 (Enzymatic) -12972ES
Process consistency	RNA-seq–ready reagents with high reproducibility	Hieff NGS™ EvoMax RNA Library Prep Kit（dNTP） _ 12341ES
GMP readiness	Scalable, automation-friendly workflows	Automated Library Preparation System + Plate-Format Library Prep Kit